Continuous progress, should fly?19 Jun 2018 15:27
21 May - MRx0518 Monotherapy trial approval from MHRA
4 June – Blautix clinical study showing positive improvement in IBS symptoms vs. Placebo
7 June – Clinical Collaboration agreement with MSD for MRx0518 and KEYTRUDAÂ
12 June – Majority shareholder notification from asset management company Janus Henderson
13 June – Clearance from MHRA and HPRA for Blautix Phase II study
Such consistent progress for some key products from this Company - amazed this is so low currently, considering where the sp was at the start of the year? 300+